Goldman Sachs: A rate cut by the Federal Reserve at the upcoming December meeting is almost a foregone conclusion
ChainCatcher News, according to Wallstreetcn, analysts from Goldman Sachs' Fixed Income, Currencies and Commodities (FICC) division believe that a rate cut by the Federal Reserve at the upcoming December meeting is essentially a foregone conclusion.
The analysts pointed out that, based on the weakening trend in the labor market and the need for risk management, a rate cut at this time is the correct policy choice, and market pricing has already fully reflected this expectation.
Comments made by Williams last Friday were sufficient to indicate that there are enough votes within the Federal Open Market Committee (FOMC) to push for a rate cut. As a result, market pricing has rebounded to 21 basis points. With the Federal Reserve officially entering its blackout period, the probability of a rate cut reflected in market pricing has risen to as high as 85%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
